Susan Mennenga
Clinical Researcher
Data updated
Papers
Trials
Research Footprint
Susan Mennenga appears in 8 tracked papers (2016–2025), most studied alongside Psilocybin and Ayahuasca, across Depressive Disorders, Anxiety Disorders and Palliative & End-of-Life Distress.
Most-cited paper: Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial (1678 citations).
Frequent co-authors: Stephen Ross, Michael Bogenschutz and Gabrielle Agin-Liebes.
Background & Research
Susan E. Mennenga is a clinical researcher involved in multiple clinical investigations of psilocybin-assisted psychotherapy, with a focus on psychiatric and existential distress in patients with life‑threatening cancer and on therapeutic processes in alcohol use disorder. Her work, as represented in several clinical papers, emphasises both quantitative clinical outcomes (including reductions in loss of meaning, suicidality, anxiety and depressive symptoms) and detailed qualitative clinical interpretations of patient experience.
Mennenga has contributed to studies reporting acute and sustained reductions in loss of meaning and suicidal ideation following psilocybin-assisted psychotherapy in oncology populations, detailed individual case narratives from cancer patients, long-term follow-up outcomes, and analyses of personality change and clinical interpretation in a double-blind, placebo-controlled trial for alcohol use disorder. Her contributions are characterised by integration of clinical assessment, psychotherapy process evaluation, and patient-centred outcome measurement, advancing understanding of both therapeutic effects and subjective experience in contemporary psychedelic-assisted therapy trials.
Key Impact
Contributor to clinical investigations of psilocybin-assisted psychotherapy, particularly for cancer-related existential distress and for alcohol use disorder, with work spanning acute, long-term and qualitative patient-outcome analyses.
Collaboration Network
10 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Susan Mennenga is associated with.
NYU Center for Psychedelic Medicine
NYU Langone Health’s Center for Psychedelic Medicine (NYU CPM) conducts health-focused translational research, education, and training on the therapeutic use of psychedelic drugs across psychiatry, medicine, and preclinical science. It supports clinical trials and a research training program to develop investigators and clinicians in the field.
View stakeholder →NYU Grossman School of Medicine
NYU Grossman School of Medicine is New York University's medical school and a core academic unit of NYU Langone Health. It provides MD and other medical education, conducts biomedical research, and delivers clinical care in the United States.
View stakeholder →NYU Langone Health
Home to the NYU Langone Center for Psychedelic Medicine, one of the world's leading academic institutions in psychedelic research. Has conducted landmark psilocybin trials for smoking cessation, alcohol use disorder, and depression in cancer patients, spearheaded by Dr. Michael Bogenschutz and colleagues.
View stakeholder →